MAIA Biotechnology Statistics
Share Statistics
MAIA Biotechnology has 25.33M shares outstanding. The number of shares has increased by 40.93% in one year.
| Shares Outstanding | 25.33M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 9.48% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 21.20M |
| Failed to Deliver (FTD) Shares | 280 |
| FTD / Avg. Volume | 0.23% |
Short Selling Information
The latest short interest is 662.41K, so 2.77% of the outstanding shares have been sold short.
| Short Interest | 662.41K |
| Short % of Shares Out | 2.77% |
| Short % of Float | 3.35% |
| Short Ratio (days to cover) | 10.99 |
Valuation Ratios
The PE ratio is -0.78 and the forward PE ratio is -1.66.
| PE Ratio | -0.78 |
| Forward PE | -1.66 |
| PS Ratio | 0 |
| Forward PS | 2 |
| PB Ratio | 32.49 |
| P/FCF Ratio | -1.19 |
| PEG Ratio | n/a |
Enterprise Valuation
MAIA Biotechnology Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.
| Current Ratio | 1.53 |
| Quick Ratio | 1.53 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -41.41% and return on capital (ROIC) is -4226.58%.
| Return on Equity (ROE) | -41.41% |
| Return on Assets (ROA) | -2.61% |
| Return on Capital (ROIC) | -4226.58% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.52M |
| Employee Count | 13 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 92.23% in the last 52 weeks. The beta is 0.34, so MAIA Biotechnology 's price volatility has been higher than the market average.
| Beta | 0.34 |
| 52-Week Price Change | 92.23% |
| 50-Day Moving Average | 2.47 |
| 200-Day Moving Average | 2.81 |
| Relative Strength Index (RSI) | 38.61 |
| Average Volume (20 Days) | 120.16K |
Income Statement
In the last 12 months, MAIA Biotechnology had revenue of $0 and earned -$19.77M in profits. Earnings per share was $-1.49.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -20.18M |
| Net Income | -19.77M |
| EBITDA | -20.18M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.49 |
Balance Sheet
The company has $7.15M in cash and $0 in debt, giving a net cash position of $7.15M.
| Cash & Cash Equivalents | 7.15M |
| Total Debt | 0 |
| Net Cash | 7.15M |
| Retained Earnings | -63.98M |
| Total Assets | 9.24M |
| Working Capital | 5.63M |
Cash Flow
In the last 12 months, operating cash flow was -$13.07M and capital expenditures -$4, giving a free cash flow of -$13.07M.
| Operating Cash Flow | -13.07M |
| Capital Expenditures | -4 |
| Free Cash Flow | -13.07M |
| FCF Per Share | -0.99 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
MAIA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -75.25% |
| FCF Yield | -26.06% |
Analyst Forecast
Currently there are no analyst rating for MAIA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -18.01 |
| Piotroski F-Score | 2 |